215 related articles for article (PubMed ID: 22588151)
1. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.
Ekman S; Wynes MW; Hirsch FR
J Thorac Oncol; 2012 Jun; 7(6):947-53. PubMed ID: 22588151
[TBL] [Abstract][Full Text] [Related]
2. [Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer].
Lin Y; Zhang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):239-42. PubMed ID: 20450558
[TBL] [Abstract][Full Text] [Related]
3. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D; Li SJ; Zhu YT; Liu L; Li MX
Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
[TBL] [Abstract][Full Text] [Related]
4. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
5. mTOR in Lung Neoplasms.
Krencz I; Sebestyen A; Khoor A
Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
7. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.
Massarelli E; Papadimitrakopoulou VA
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S379-82. PubMed ID: 23160325
[No Abstract] [Full Text] [Related]
9. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
Cuffe S; Leighl NB
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1805-7. PubMed ID: 22005538
[No Abstract] [Full Text] [Related]
10. The role of targeting mammalian target of rapamycin in lung cancer.
Pal SK; Figlin RA; Reckamp KL
Clin Lung Cancer; 2008 Nov; 9(6):340-5. PubMed ID: 19073516
[TBL] [Abstract][Full Text] [Related]
11. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Papadimitrakopoulou V
J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
13. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Mammalian Target of Rapamycin in Lung Cancer.
Vicary GW; Roman J
Am J Med Sci; 2016 Nov; 352(5):507-516. PubMed ID: 27865299
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors in cancer therapy.
Zaytseva YY; Valentino JD; Gulhati P; Evers BM
Cancer Lett; 2012 Jun; 319(1):1-7. PubMed ID: 22261336
[TBL] [Abstract][Full Text] [Related]
16. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
17. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
18. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
19. An overview of the mTOR pathway as a target in cancer therapy.
Gentzler RD; Altman JK; Platanias LC
Expert Opin Ther Targets; 2012 May; 16(5):481-9. PubMed ID: 22494490
[TBL] [Abstract][Full Text] [Related]
20. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
Papadimitrakopoulou V; Adjei AA
J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
